Articles
The German biotech startup Mallia Therapeutics (formerly MalliaBiotech) has secured seed funding to further its hair loss drug soluble CD83. CD83 Hair Growth Through Immune Modulation On July 11, 2023, Mallia Therapeutics issued a press release announcing a successful seed financing round and the presentation of data at a European Hair Research Society (EHRS) meeting.…
Life Code shares poster from the 25th World Congress of Dermatology Singapore 2023 with Follicle Thought. Artificial Intelligence Small Molecule Enhanced Hair Growth Follicle Thought is pleased to share an exclusive look at Life Code’s poster from the current World Congress of Dermatology event. Just over a year ago, I shared an introduction to Life…
On June 28, 2023, Amplifica Holdings Group announced the initiation of a clinical trial for one of its lead candidate molecules from the study of hairy moles. Amplifica’s AMP-303 has officially entered a clinical trial. According to a news release on the company’s website and PR Newswire, the first patient was dosed in a multicenter,…
Things are really heating up in the hair loss treatment industry on the first day of Summer 2023. Let’s take a look at all pertinent information and happenings in the AGA clinical trial world below. Cosmo Pharma Lists Phase 3 Trial On ClinicalTrials.gov A trial which was once highly anticipated, then questioned if it would…
Follicle Thought is pleased to announce a new company developing a treatment for androgenetic alopecia with an innovative technology. Unlike most other biotechs tackling the challenging field of hair regeneration, StimuSIL is a biomedical device company. Their team has created a completely new way to deliver photobiomodulation and incorporated it into a proprietary, patented hair…
A company working in protein degradation has entered the field of hair loss therapeutics in Spring 2023 with a new anti-hair loss drug. AH-001 AnHorn Medicines As I’ve stated before, we are in a new era for hair loss medication. Whereas in years past we would see a new therapy or company emerge once per…
An Indian drug-discovery startup with a focus on dermatology has unveiled its new website. Inovaugmet Research, which was mentioned in a recent article on Follicle Thought, is aiming to bring new therapies to unmet dermatological needs. Inovaugmet utilizes a dermatology-specific drug discovery platform called iNeu-3D screen to find new molecules. From the company’s website, iNeu-3D…
After a more thorough evaluation of FOL-005’s data from a phase 2 clinical trial, new management at Follicum believes that its drug candidate has a place in the treatment landscape for androgenic alopecia and they want to explain why. FOL-005 Phase 2 Results Revisited In February 2022, Follicum AB was acquired by Coegin Pharma, a…
On May 11, 2023, Kintor Pharmaceutical of China announced results from their US phase 2 trial testing KX-826 aka pyrilutamide in males with androgenetic alopecia. Successful Phase 2 Trial For US KX-826 Trial As is the trend for Kintor Pharmaceutical’s AGA programs, today’s announcement included positive results in a human trial. This milestone will help…
A new brief update has been shared about the official launch of the anticipated cosmeceutical CosmeRNA from the siRNAgen & Bioneer companies. CosmeRNA is a topical siRNA serum which inhibits the production of the androgen receptor protein using small interfering RNAs. It has been clinically tested in Korea, and Europe through the Dermatest agency and…